- Home
- ASLE vs CRDF Comparison
ASLE vs CRDF Comparison
Compare ASLE & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASLE
- CRDF
- Stock Information
- Founded
- ASLE 2008
- CRDF 1999
- Country
- ASLE United States
- CRDF United States
- Employees
- ASLE N/A
- CRDF N/A
- Industry
- ASLE Industrial Specialties
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ASLE Consumer Discretionary
- CRDF Health Care
- Exchange
- ASLE Nasdaq
- CRDF Nasdaq
- Market Cap
- ASLE 277.0M
- CRDF 233.5M
- IPO Year
- ASLE N/A
- CRDF N/A
- Fundamental
- Price
- ASLE $8.63
- CRDF $2.08
- Analyst Decision
- ASLE Hold
- CRDF Strong Buy
- Analyst Count
- ASLE 2
- CRDF 6
- Target Price
- ASLE $7.00
- CRDF $10.58
- AVG Volume (30 Days)
- ASLE 602.4K
- CRDF 1.2M
- Earning Date
- ASLE 08-06-2025
- CRDF 07-29-2025
- Dividend Yield
- ASLE N/A
- CRDF N/A
- EPS Growth
- ASLE N/A
- CRDF N/A
- EPS
- ASLE 0.13
- CRDF N/A
- Revenue
- ASLE $350,583,000.00
- CRDF $545,000.00
- Revenue This Year
- ASLE $9.98
- CRDF N/A
- Revenue Next Year
- ASLE $8.15
- CRDF N/A
- P/E Ratio
- ASLE $70.13
- CRDF N/A
- Revenue Growth
- ASLE N/A
- CRDF N/A
- 52 Week Low
- ASLE $4.53
- CRDF $2.06
- 52 Week High
- ASLE $9.12
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- ASLE 65.59
- CRDF 31.67
- Support Level
- ASLE $8.74
- CRDF $2.08
- Resistance Level
- ASLE $9.12
- CRDF $2.39
- Average True Range (ATR)
- ASLE 0.33
- CRDF 0.11
- MACD
- ASLE -0.05
- CRDF 0.02
- Stochastic Oscillator
- ASLE 32.88
- CRDF 11.46
About ASLE AerSale Corporation
AerSale Corp is an integrated, diversified leader in aviation aftermarket products and services. It specializes in the sale, lease, and exchange of used aircraft, engines, and components, in addition to providing a broad range of maintenance, repair, and overhaul, and engineering services for commercial aircraft and components. The company operating segment includes Asset Management Solutions and TechOps. It generates maximum revenue from the Asset Management Solutions segment.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.